Abstract
Introduction: At least 50% of individuals who suffer sudden cardiac arrest (SCA) experience warning symptoms before their SCA. We have previously reported chest pain and dyspnea as the most common and potentially predictive symptoms. Combining with clinical features could improve sensitivity and specificity for prediction of imminent SCA (ISCA). Hypothesis: A combination of warning symptoms and clinical profiles can predict ISCA. Methods: From two community-based studies of SCA in Oregon and California, we conducted a case-control study. Cases (n=364) were survivors of SCA who had experienced warning symptoms, and control subjects (n=313) were individuals who notified emergency medical services (EMS) for similar symptoms but did not have SCA. Symptom data were obtained from interviews with study subjects and from EMS pre-hospital care records. We constructed classification and regression tree (CART) models for major symptom categories to identify clinical predictors of ISCA. We used the area under the receiver operating characteristic curve (AUC) and 5-fold cross-validation to assess model performance and stability. Results: Heart failure (HF) and/or coronary artery disease (CAD) were predictors of ISCA and displayed important sex differences. For example, among individuals presenting with only chest pain, male sex, particularly males with HF, was an important predictor of ISCA (AUC = 0.813). Among individuals with only dyspnea, CAD and HF were important predictors (AUC = 0.745) with no sex differences identified. The 5-fold cross-validation produced consistent results. Conclusions: Combinations of warning symptoms and clinical features distinguished individuals with SCA from individuals without SCA with good accuracy (AUCs 0.728-0.813).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Chugh has received funding from National Institutes of Health, National Heart Lung and Blood Institute Grants R01HL147358 and R01HL145675 for this work. Dr. Chugh holds the Pauline and Harold Price Chair in Cardiac Electrophysiology at Cedars-Sinai, Los Angeles. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The PRESTO study was approved by the Institutional Review Boards (IRBs) of Ventura County Medical Center, Cedars-Sinai Health System, and all other participating health systems; the SUDS study was approved by the IRB of Oregon Health and Science University and all other participating health systems. All survivors of cardiac arrest and control subjects provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.